摘要
采用白细胞介素２（ＩＬ－２）输注，并联合应用经ＩＬ－２诱导的来源于自体外周血，胎儿胸腺，脾脏及脐带血的淋巴因子激活的杀伤细胞（ＬＡＫ细胞）治疗１４例血液肿瘤患者（急性白血病１０例，恶性淋巴瘤４例）。其中１例异基因骨髓移植后复发的急性淋巴细胞白血病患者经过以门冬酰胺酶，长春新碱，柔红霉素，足叶乙甙等药物为主的５个疗程的联合化疗后仍未缓解，再给予ＤＯＬＰ（柔红霉素、长春新碱、门冬酰胺酶、强的松）方案１个疗程并联合应用ＩＬ－２／ＬＡＫ细胞疗法１个疗程后，骨髓示完全缓解并持续３个月。另１例复发的何杰金氏病患者，在接受了２个疗程的ＩＬ－２ｌ／ＬＡＫ细胞疗法后，其颈部肿块明显缩小。其余１２例系在完全缓解期接受该疗法。我们所用ＩＬ－２的剂量为４×１０４～５×１０５Ｕ／ｄ；初步结果表明该疗法安全有效，未见明显毒副作用。
In this study,we
initiated a phase I clinical trial of interleukin-2(IL-2)and lymp- hokine-activated killer(LAK) cells
in 14 patients with hematological malignancies(10 acute leu- kemia,4 lymphoma).They were
well tolerable for IL-2 at dose of 4×104u/d～5 × 105u/d combi- ning with the LAK cells
induced from peripheral blood cells,cord blood cells,foetal thymus or spleen cells.The major
toxicities were fever and chills.In these patients,12 were in compelet remission(CR)and one of
the others was a refractory ALL who didn’t achieved a remission after 5 cycles of combinant
chemotherapy based on L-ASP,DNR,6～MP,VP16,VCR and he achieved a second CR after a
DOLP chemotherapy followed by one cycle of IL-2/LAK cells therapy.Ano- ther case was a
relapsed Hodgkin’s disease and the toumor was obviously reduced after two cycles of
IL-2/LAK cells therapy.The preliminary results indicated that infusion of IL-2 at the above doses
with LAK cells is safe and may be an effective treatment for patients with acute leukemia and
lymphoma after BMT or chemotherapy.
出处
《军医进修学院学报》
CAS
1994年第3期168-171,共4页
Academic Journal of Pla Postgraduate Medical School
